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Objective: In physiological conditions, the liver plays an important role in the regulation of plasma arginine concentrations by
taking up large amounts of arginine from the hepatic circulation. When hepatic failure is present, arginine metabolism may be
disturbed. Therefore, we hypothesized high arginine plasma concentrations in critically ill patients suffering from hepatic failure.
Design: We prospectively collected blood samples from a cross-section of intensive care unit patients.
Setting: Surgical intensive care unit of a Dutch university medical center.
Subjects: A total of 52 critically ill patients with clinical evidence of dysfunction of more than two organs were recruited.
Measurements: Plasma arginine concentrations were determined by HPLC. We identified correlations of arginine
concentrations with organ failure scores and laboratory variables by univariate and multiple regression analyses.
Results: High plasma arginine concentrations were found in critically ill patients developing organ failure. Patients who were in
the highest quartile of plasma arginine concentrations had significantly lower fibrinogen concentrations, higher lactic acid
concentrations, and longer prothrombin time. Stepwise multiple regression analysis showed that concentrations of arginine
were independently associated with the presence of hepatic failure (P¼0.03) and renal failure (P¼0.048). In addition, lactic
acid proved to be an independent determinant of plasma arginine concentration (P¼0.014).
Conclusions: Critically ill patients who suffer from hepatic failure have elevated plasma arginine concentrations. Additional
arginine in the treatment of these patients can be harmful, and therefore should not be used as a standard nutritional regimen
until further evaluation.
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Introduction
In unstressed animals and humans, arginine might be
classified as a dispensable amino acid, but when the
degradation and/or utilization is increased, such as in wound
healing, trauma, and sepsis, arginine becomes an indispen-
sable amino acid. Therefore, arginine is considered as a
conditionally essential amino acid.
Arginine has multiple biological functions: it enhances
wound healing (Barbul et al, 1990), improves immune
function (Reynolds et al, 1988) and T-cell antitumor
immunity (Barbul et al, 1985), has anticatabolic effects
(Barbul et al, 1984), plays an important role in the urea
cycle by eliminating nonessential nitrogen-containing com-
pounds from the body (Brusilow & Horwich, 1989), and is
the sole precursor of nitric oxide (NO) (Palmer et al, 1988).
NO is an important vasodilator and plasma concentrations
of arginine seem to be rate limiting in NO synthesis (Nakaki
et al, 1990; Creager et al, 1992; Lorente et al, 1999), thereby
playing a major role in the regulation of systemic and
splanchnic circulation in both normal and pathologicalReceived 17 January 2003; revised 23 May 2003; accepted 30 June 2003
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situations. In a study in rats, we observed a reduced blood
flow to the small intestine when plasma concentrations of
arginine were low in the presence of low-grade endotoxemia
(Prins et al, 2000a). Circulating arginine is reduced in a
number of clinical conditions, for example, after thoracoab-
dominal aortic surgery (Nijveldt et al, 2000), after surgery for
esophageal and lung cancer (Naini et al, 1988), after trauma
(Houdijk et al, 1998), during sepsis (Freund et al, 1978), and
in severe burns (Yu et al, 1995). Because of the many
physiological functions of arginine, low levels of this amino
acid may be related to the high morbidity and mortality rates
in these patient groups. In order to study the effect of
arginine on postoperative morbidity and mortality, arginine-
enriched nutrition has been tried in patients undergoing
major elective surgery. A recent meta-analysis proved that
immune-enhancing diets containing arginine reduce the
number of infectious complications and duration of hospital
stay in surgical patients (Heyland et al, 2001). However,
immunonutrition containing arginine in critically ill pa-
tients was not associated with any apparent clinical benefit.
Moreover, it has recently been shown that intensive care unit
(ICU) mortality in septic patients was significantly higher in
patients receiving enteral arginine-enriched nutrition com-
pared to patients receiving parenteral nutrition (Bertolini
et al, 2003). Nevertheless, not much is known about the
underlying mechanism by which arginine-enriched nutri-
tion may possibly be harmful. It has been shown that dietary
arginine supplementation decreases the mRNA expression of
inflammatory cytokines in burned rats (Cui et al, 2000), and
that pharmacological doses of arginine are immunosuppres-
sive by inhibiting lymphocyte proliferation in vitro (Wiebke
et al, 1997). Furthermore, arginine is known to be a
stimulator of growth hormone synthesis, and growth
hormone therapy in critically ill patients results in adverse
outcome (Takala et al, 1999). In patients with renal
insufficiency, arginine supplementation can lead to cardio-
toxic plasma potassium concentrations (Hertz & Richardson,
1972). Another negative effect of arginine can be over-
production of NO in organs that already are challenged by
enormous amounts of NO formed by the enzyme-inducible
NO synthase. High concentrations of NO may further
aggravate tissue damage by inhibiting enzymes of oxidative
substrate utilization and nuclear DNA synthesis, but also by
increased formation of peroxynitrite which has many
deleterious actions on cell function.
The liver plays a crucial role in the metabolism of
arginine. In healthy subjects, large amounts of arginine
are taken up from the portal venous and hepatic
arterial blood supplies, probably to serve as a substrate in
the urea cycle. The liver has therefore been called the major
sink of arginine. The effect of liver injury on arginine
concentrations is not yet fully understood, because both
low (Roth et al, 1994; Houdijk et al, 1997) and high (Prins
et al, 2000b) plasma arginine concentrations after liver
surgery have been reported in human studies and animal
models.
Critically ill patients may suffer from hepatic failure, and
consequently arginine uptake capacity of the liver and
subsequent degradation of arginine by the enzyme arginase
may be reduced. We hypothesized high plasma arginine
concentrations in these patients and, therefore, we deter-
mined arginine concentrations in critically ill patients who




In this prospective cross-sectional study, blood samples were
drawn from 52 consecutive patients who were admitted to
the surgical ICU of a Dutch university hospital. The protocol
was approved by the institutional review boards, and
informed consent was obtained from first-degree family
members.
From April 2001 to December 2001, at weekly intervals,
the senior intensivist of the surgical intensive care unit
judged on the suitability for inclusion. Patients were
included if they met both criteria: (1) clinical evidence of
dysfunction of Z2 organs, irrespective of the cause of organ
dysfunction; (2) calculated total sequential organ failure
assessment score Z6 (SOFA score (Vincent et al, 1996),
Table 1). Organ failure was defined as a SOFA score Z 3 for
any system.
Blood sampling
After inclusion, a heparinized blood sample (0.5 ml) was
drawn from an indwelling arterial line. Laboratory variables
that indicate renal function (creatinine and urea), hepatic
function (prothrombin time (PT), fibrinogen, and lactic
acid), and hepatic enzyme abnormalities (alanine amino-
transferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase (AP), and bilirubin) were determined. Plasma
arginine concentrations were determined by HPLC as
previously described (Teerlink et al, 2002).
Statistical analysis
Differences between two groups were tested using the
nonparametric Mann–Whitney U-test. Results are presented
as median and interquartile range (IQR). Multiple regression
analysis was performed to determine the interdependent
effects of variables on arginine concentrations. The regres-
sion equation was built step by step, in each step including
the then most significant variable. Relations between
variables were investigated using Pearson’s correlation.
Logarithmic transformation was performed when data were
not normally distributed, as in the case of arginine, ALT, AST,
bilirubin, AP, PT, lactic acid, creatinine, and urea. Po0.05
was considered statistically significant. Statistical analyses
were performed using SPSS (SPSS 10.0 for Windows).
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Results
In total, 52 critically ill patients entered the study. Demo-
graphic data of the study population are given in Table 2.
Median plasma concentrations of arginine, fibrinogen,
lactic acid, and PT in critically ill patients are shown in
Table 3. From the patients who were in the highest quartile
of arginine concentrations (arg(Z109): 109–454 mmol/l), six
patients suffered from hepatic failure and four patients from
renal failure.
Patients who were in the highest quartile of arginine had,
as liver function variables, significantly lower fibrinogen
concentrations (arg(Z109): 2.5 g/l, IQR 1.1–4.4; arg(o109):
4.4 g/l, IQR 3.5–5.7, P¼0.013), higher lactic acid concentra-
tions (arg(Z109): 3.80 mmol/l, IQR: 1.47–7.35; arg(o109):
1.70 mmol/l, IQR 1.20–2.20, P¼0.029), and longer PT
(arg(Z109): 22.10 s, IQR: 19.90–39.09; arg(o109): 18.70 s, IQR:
15.40–25.00, P¼0.03). However, there were no significant
differences for the indicators of hepatic enzyme abnormal-
ities (AST, ALT, bilirubin, and alkaline phosphatase) and
renal function (creatinine and urea).
Multiple regression analysis showed that plasma
concentrations of arginine in all critically ill patients
were independently associated with the presence of
hepatic failure and renal failure (Table 4). Of note is
the negative sign for renal failure, indicating a reduction
of plasma arginine concentrations when renal failure is
present.
Arginine concentration in all patients was positively
correlated with lactic acid (r¼0.338, P¼0.014) and
negatively correlated with fibrinogen (r¼0.306,
P¼0.027), but not to the other indicators of hepatic
enzyme abnormalities or hepatic and renal function. By
multiple regression analysis, lactic acid proved to be an
independent determinant of plasma arginine concentration
(Table 4).
Discussion
In this study, we clearly demonstrate seriously elevated (up
to 454 mmol/l) plasma concentrations of arginine in critically
ill patients. Plasma arginine concentrations were indepen-
dently associated with the presence of both liver and renal
Table 1 SOFA score
SOFA score 0 1 2 3 4
Respiration
PaO2/FiO2 (mmHg) >400 301–400 201–300 101–200 r100
(kPa) >5.3 4.1–5.3 2.8–4.0 1.4–2.7 r1.3
Coagulation
Platelets (103/mm3) >150 101–150 51–100 21–50 r20
Liver
Bilirubin (mg/dl) o1.2 1.2–1.9 2.0–5.9 6.0–11.9 Z12.0
(mmol/l) o20 20–32 33–101 102–204 Z204
Cardiovascular
Hypotension No hypotension MAP o70 mmHg Dopamine r5 or dobutamine (any dose)a Dopamine >5 Dopamine >15
Central nervous system
Glasgow coma score 15 13–14 10–12 6–9 o 6
Renal
Creatinine (mg/dl) o1.2 1.2–1.9 2.0–3.4 3.5–4.9 >5.0
(mmol/l) o110 110–170 171–299 300–440 >440
or urine output o500 ml/day o200 ml/day
aAdrenergic agents administered for at least 1 h (doses are in mg/kg/min). MAP=mean arterial pressure.
Table 2 Demographic data of the patient population
Number of patients 52
Gender: male/female 34/18
Age (y): median (range) 58 (16–81)
Type of admission
Complicated course after elective surgery 17 (32.7%)
Polytrauma 10 (19.2%)
Peritonitis, multiple perforations 10 (19.2%)
Decompensated liver cirrhosis 5 (9.6%)
Necrotizing pancreatitis 4 (7.7%)
Other 6 (11.5%)
Organ failures (SOFA score per organ sytem Z3)
Hepatic failure 14 (26.9%)
Renal failure 19 (36.5%)
Hepatic and renal failure 10 (19.2%)
Neurological failure 15 (28.9%)
Respiratory failure 32 (61.5%)
Coagulation failure 10 (19.2%)
Cardiovascular failure 33 (63.5%)




ICU death 21 (40.4%)
Data are number of patients. Numbers in parentheses are percentages of
total patient population unless otherwise stated. SOFA=sequential organ
failure assessment; ICU=intensive care unit.
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failure. Furthermore, lactic acid, as an indicator of hepatic
function, was an independent determinant of arginine
concentration.
Critically ill patients may suffer from failure of the liver
and kidney. These organs are important in the metabolism of
arginine. The kidney synthesizes arginine from citrulline and
a nitrogen donor, usually aspartic acid (Borsook & Dubnoff,
1941). In patients with chronic renal failure, it has been
shown that a net citrulline uptake was balanced by an equal
net arginine output, which on the overall was 40% less than
in healthy humans (Tizianello et al, 1980). In our study, we
show that plasma concentrations of arginine are indepen-
dently and negatively associated with the presence of renal
failure in critically ill patients. This finding is in concordance
with the role of the kidney as arginine synthesizing organ as
demonstrated by Prins et al (2002). In that study, it was
demonstrated in a rat model that arginine production was
impaired after ischemia–reperfusion injury of the kidney.
Thus, reduced arginine levels in this patient group could be
explained by a deteriorated synthesizing function of the
kidney. In addition, we proved that high arginine concen-
trations are independently associated with the presence of
hepatic failure. The liver is a crucial organ in the metabolism
of arginine because it contains large amounts of the enzyme
arginase, which converts arginine into ornithine and urea in
the urea cycle (Jackson et al, 1986). In physiological
conditions, large amounts of arginine are taken up from
the hepatic circulation, most likely to serve as substrate for
arginase. However, the effect of liver injury on plasma
arginine concentrations is still not clear. Results of studies on
the level of arginine concentrations after liver surgery are
contradictory. Roth et al (1994) reported very low arginine
concentrations (3.8 mmol/l) after liver transplantation due to
liberation of high amounts of arginase from the implanted
graft. Arginine deficiency also occurred in bile duct-ligated
rats undergoing surgery (Houdijk et al, 1997). The decline of
arginine was caused by high liver arginase activity in plasma.
Administration of cholestyramine, as inhibitor of gut-
derived endotoxemia, in these rats, prevented the arginine
deficiency by reducing arginase activity through the inhibi-
tion of additional endotoxin-mediated hepatocellular da-
mage after surgery. On the other hand, high concentrations
of arginine have also been reported; in a rat model, Kupffer-
cell depletion resulted in a higher arginase release from the
remnant liver after partial hepatectomy, indicating a hepa-
tocellular protective function of Kupffer cells. Despite this
arginase release, increased arginine concentrations were
present (Prins et al, 2000b).
In critically ill patients, we found high arginine concen-
trations and, therefore, dietary enrichment with arginine in
the treatment of these patients needs to be questioned.
It could be argued that the need for additional arginine
seems to be determined by an increased demand during
stressed states. During stress, cationic amino acids as
arginine are released from skeletal muscle, and are trans-
ported into the liver by cationic amino-acid transporters
Table 3 Concentrations of arginine (mmol/l), lactic acid (mmol/l), fibrinogen (g/l), and PT (s)
Arginine Lactic acid Fibrinogen PT
All patients (n=52) 68 1.8 4.1 19.9
(46–109) (1.2–3.0) (2.7–5.4) (15.9–25.1)
No liver or renal failure (n=29) 73 1.6 4.4 19.2
(49–106) (1.1–2.2) (3.6–5.7) (15.4–23.5)
Liver failure, no renal failure (n=4) 285 7.3 1.4 28.3
(72–319) (3.2–7.9) (1.1–4.0) (20.8–38.3)
Renal failure, no liver failure (n=9) 54 1.7 4.6 18.7
(33–89) (1.1–3.5) (2.8–5.8) (16.2–27.0)
Liver and renal failure (n=10) 58 3.2 3.6 20.0
(47–181) (1.6–7.3) (1.6–4.0) (17.6–54.7)
Data are presented as median (IQR). PT=prothrombin time.
Table 4 Multiple regression models for both organ failure (SOFA score
per organ sytem Z3) and biochemical markers of hepatic and renal
function as determinants of plasma arginine concentration
b Standardized b P r 2
Model 1: Organ failures
Hepatic failure 0.307 0.450 0.030 0.103
Renal failure 0.185 0.294 0.048 0.172
Model 2: Biochemical markers
Lactic acid 0.308 0.338 0.014 0.114
As potential explanatory variables for plasma arginine concentration, organ
failures (hepatic, renal, coagulation, respiratory, cardiovascular, and neurolo-
gical failure) or biochemical markers of hepatic (AST, ALT, bilirubin, alkaline
phosphatase, fibrinogen, PT, and lactic acid) and renal (creatinine and urea)
function were entered in the analysis.
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(CAT) of the system yþ (Closs et al, 2000). Interestingly,
Hattori et al (1999) showed that the expression of CAT-1 and
CAT-2B mRNA was significantly increased in lung, heart, and
kidney by injection of lipopolysaccharide (LPS), whereas in
the liver CAT-2A mRNA was abundantly expressed, indepen-
dently of LPS administration. Therefore, changes in the
expression of CAT mRNA may influence arginine transport,
and the abundant expression of CAT-2 mRNA in the liver
points to a potentially high uptake of arginine in this organ.
Thus, transport mechanisms may determine intracellular
concentrations, and are therefore probably important as
regulators of the arginine–NO pathway. Interestingly, argi-
nine transporters have been held responsible for the
‘arginine-paradox’, the observation that endothelial NO
synthesis can be regulated by varying the extracellular
arginine concentration, despite the fact that the reported
intracellular arginine concentrations (0.1–1.0 mM) greatly
exceed the Km of endothelial nitric oxide synthase (NOS) for
arginine (2.9 mM) (Wu & Morris Jr, 1998). Interstingly, Lee
et al (2003) recently demonstrated in an in vitro model that
arginine concentration upregulates iNOS expression via
translational control of iNOS mRNA.
As the liver plays a crucial role in the metabolism of
arginine, hepatic failure may affect arginine concentration.
To determine liver function in our study population, we
measured multiple hepatic parameters. Patients who were in
the highest quartile of arginine concentrations had lower
fibrinogen concentrations, longer PT, and higher lactic acid
concentrations, indicating impairment of hepatic function.
In addition, high lactic acid concentrations were an
independent determinant of arginine concentrations.
In our opinion, the crucial role of the liver in the
metabolism of arginine is neglected in studies on arginine-
enriched nutrition in critical illness. Moreover, hepatic
failure may be a contraindication for the supplementation
of arginine-enriched nutrition. Additional arginine could be
potentially harmful instead of beneficial in this condition.
How can arginine possibly be harmful? Cationic amino
acids such as arginine cause movement of potassium ions
from (muscle) cells to the extracellular compartment. This
displacement is associated with an immediate increase in
potassium excretion by the kidney (Alberti et al, 1967).
When the excretion of potassium is impaired, as in end-stage
renal disease, detrimental increases in potassium concentra-
tions have been reported (Hertz & Richardson, 1972).
Moreover, hyperkalemia has also been reported in patients
with severe liver failure and only moderate renal insuffi-
ciency (Bushinsky & Gennari, 1978). Other reported disturb-
ing effects of arginine on electrolyte metabolism include
hyponatremia (Alberti et al, 1967) and hypophosphatemia
(Massara et al, 1980). Thrombocytopenia (Mudge, 1980) and
hypotension (Nakaki et al, 1990) due to arginine supple-
mentation have also been described. It has also been
reported that caution should be taken in recommending
arginine-enriched nutrition as a method to reverse clinical
immunosuppression. Pharmacological doses of arginine
have been shown to be immunosuppressive by reversible
inhibition of lymphocyte proliferation in vitro (Wiebke et al,
1997). In burned rats, arginine enrichment decreases
expression of inflammatory cytokines in organs (Cui et al,
2000). Furthermore, arginine is known to be a stimulator of
growth hormone synthesis. The administration of growth
hormone can attenuate the catabolic response during injury,
surgery, and sepsis. Nevertheless, in critically ill patients,
high doses of growth hormone resulted in adverse outcome
(Takala et al, 1999). Another possible negative effect of
arginine can be overstimulation of NO synthesis in organs
that already are challenged by large amounts of NO
produced by the enzyme-inducible NO synthase. NO is able
to react with so-called reactive oxygen species, thereby
forming peroxynitrite that may damage cell membranes,
oxidize lipids, and inhibit enzyme function. Other harmful
effects of overproduction of NO affect the cardiovascular
system and consist of coagulation disorders and systemic
vasodilation with therapeutically refractory hypotension.
Nutritional support with arginine has been shown to
improve outcome in surgical patients (Heyland et al, 2001).
However, Nelson (1998) points out that findings in patients
undergoing surgery cannot be extrapolated to patients who
are critically ill. This statement is supported by a recent
meta-analysis of Heyland et al (2001), who showed that the
treatment effect of immune-modulating diets containing
arginine in surgical patients was significantly different from
the treatment effect in critically ill patients. Moreover, the
authors postulated that this arginine-enriched nutrition may
be harmful. Previous studies support the finding that
immunonutrition with arginine may have adverse effects.
In a randomized trial, Bower et al (1995) compared immune-
enhancing nutrition with standard enteral nutrition. Of 147
patients who received the experimental formula, 23 (15.7%)
died compared to 10 of 132 (7.6%) patients in the control
group. In a subgroup analysis, the mortality in critically ill
patients was 11.7% in the experimental group, whereas
6.9% died in the control group. Furthermore, in a study
by Dent et al (2003), 170 critically ill patients were
randomized to receive either immunonutrition containing
arginine or isonitrogenous control nutrition. In the arginine-
enriched group, there were significantly more deaths than in
the control group (23.0 vs 9.6%, P¼0.03). However, at
baseline, there were more patients with pneumonia in the
experimental group in which most deaths occurred (argi-
nine-enriched group 38.5% vs control group 0%). In a very
recent interim analysis of a multicenter, randomized,
unblinded trial on 39 patients with severe sepsis, the effect
of immune-enhancing (containing arginine) enteral feed was
compared with parenteral feed (Bertolini et al, 2003). The
ICU mortality proved to be significantly higher in the enteral
feeded group (44.4%) than in the parenteral feeded group
(14.3%). These results show that additional arginine
should not be used in septic patients (Heyland & Samis,
2003), whereas it may be beneficial in other groups of ICU
patients.
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Our data show that in different clinical states, arginine is
abundantly available or lacking. Therefore, arginine supple-
mentation is questionable in patients with hepatic failure,
whereas it may be potentially indicated in patients suffering
from renal failure.
In conclusion, we found elevated plasma concentrations
of arginine in critically ill patients. High arginine concentra-
tions proved to be associated with the presence of hepatic
failure, whereas low arginine concentrations proved to be
associated with the presence of renal failure. Arginine
supplementation is presented to be advantageous. However,
these data indicate that arginine-enriched enteral formulas
may not be used as a standard nutritional regimen in each
ICU patient. Possibly, the choice to treat patients with
additional arginine should be tailored to the individual
patient.
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